—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Arrowhead Pharmaceuticals Inc (ARWR) — chart, structure and Closelooknet read

The Closelooknet read

Arrowhead Pharmaceuticals develops RNA interference medicines aimed at chronic diseases, using its own delivery technology to silence disease-causing genes in the liver and other tissues. Its pipeline covers candidates for lipid disorders, kidney disease and other conditions, several partnered with larger drugmakers such as Takeda, Amgen and GlaxoSmithKline.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ARWR, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 46/100 · S&P 500 fund at 50, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-02
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 76th percentile of the window, -20.6% over 20 sessions. Factor regime → 2026-11-02
  • Sector × region Health care in US: +3.0% week · +11.1% month · +14.3% quarter · +26.9% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-02
  • Sovereign pressure Index -1.63 · down 2.22 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-02
How it trades on rate days beta 0.81 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How ARWR has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.81 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Arrowhead Pharmaceuticals Inc moved 0.81% on average · correlation 0.13 · higher than 73% of US names
  • Beta, last 3 months 0.83 about the same as over the year
  • On the 10 worst bond days −0.40% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −1.33% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against ARWR on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Arrowhead Pharmaceuticals Inc

ARWR in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Arrowhead Pharmaceuticals develops RNA interference medicines aimed at chronic diseases, using its own delivery technology to silence disease-causing genes in the liver and other tissues. Its pipeline covers candidates for lipid disorders, kidney disease and other conditions, several partnered with larger drugmakers such as Takeda, Amgen and GlaxoSmithKline. It is based in Pasadena, California.
Where it sits in the stack
Arrowhead carries no seat in our indices; it sits in the Healthcare sector of Closelooknet's US universe, grouped with clinical-stage biotechnology names developing RNA interference therapeutics for chronic disease, rather than in any AI infrastructure sleeve.
Who it is priced against
The peer group draws on other scored healthcare names based in the US, including Regeneron, Vertex and BeiGene; the market also compares Arrowhead with Alnylam Pharmaceuticals as another RNA interference developer.
Why Closelooknet tracks it
Arrowhead carries a Closelooknet score, with momentum the strongest module and valuation the weakest; it holds no seat in our indices and the diary has not yet quoted it in its editions.
What the diary watches
The diary watches whether pipeline candidates advance through their trial phases and whether partner collaborations expand, since either would alter the read on the shares.

Arrowhead Pharmaceuticals Inc (ARWR) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 44/100 composite (momentum 22, quality 35, valuation 13) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What ARWR pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +11.7% in FY2025 63 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-03

Quick answers

What is Arrowhead Pharmaceuticals Inc (ARWR)?

Arrowhead Pharmaceuticals Inc trades as ARWR on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-03.

Is ARWR in a Closelooknet index?

Not currently — Arrowhead Pharmaceuticals Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-03.

What is Arrowhead Pharmaceuticals Inc's Closelooknet composite score?

44 out of 100, with momentum 22, quality 35 and valuation 13 sub-scores, as of 2026-11-03. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does ARWR trade against its moving averages?

Arrowhead Pharmaceuticals Inc trades 14.0% below its 50-day and 16.9% below its 200-day moving average (0.3% above its 20-day). As of 2026-11-02 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Arrowhead Pharmaceuticals Inc compare with its peers?

Against its peer group (Biotechnology · US), Arrowhead Pharmaceuticals Inc (ARWR) sits 37.6% below its 52-week high, 14.0% below its 50-day average; Halozyme Therapeutics Inc (HALO) is 3.8% below, BeiGene, Ltd. (ONC) is 7.0% below, argenx NV ADR (ARGX) is 18.4% below, as of 2026-11-02. Put any of them next to ARWR in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Arrowhead Pharmaceuticals Inc trade when bond yields rise?

Over the past year Arrowhead Pharmaceuticals Inc had a beta of 0.81 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 73% of US names. On the 10 sessions in which long bonds fell most it moved −0.40% on average, against −0.74% for the S&P 500. As of 2026-11-02; The "How it trades on rate days" block on this page carries the lines.

What does Arrowhead Pharmaceuticals Inc do?

Arrowhead Pharmaceuticals develops RNA interference medicines aimed at chronic diseases, using its own delivery technology to silence disease-causing genes in the liver and other tissues. Its pipeline covers candidates for lipid disorders, kidney disease and other conditions, several partnered with larger drugmakers such as Takeda, Amgen and GlaxoSmithKline. It is based in Pasadena, California. The peer group draws on other scored healthcare names based in the US, including Regeneron, Vertex and BeiGene; the market also compares Arrowhead with Alnylam Pharmaceuticals as another RNA interference developer. (Company snapshot of 2026-09-17.)

Where does Arrowhead Pharmaceuticals Inc sit in the AI build-out?

Arrowhead carries no seat in our indices; it sits in the Healthcare sector of Closelooknet's US universe, grouped with clinical-stage biotechnology names developing RNA interference therapeutics for chronic disease, rather than in any AI infrastructure sleeve. Arrowhead carries a Closelooknet score, with momentum the strongest module and valuation the weakest; it holds no seat in our indices and the diary has not yet quoted it in its editions. (Company snapshot of 2026-09-17.)

Does Arrowhead Pharmaceuticals Inc pay a dividend?

No cash distribution shows in Arrowhead Pharmaceuticals Inc’s price series over the last three years. The share count rose 11.7% over the fiscal year. As of 2026-11-02; the "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for ARWR, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.